BRIEF-Tenaya Therapeutics Announces Updates On TN-201 Gene Therapy Program For MYBPC3-Associated HCM

Reuters10-18

Oct 17 (Reuters) - Tenaya Therapeutics Inc :

* TENAYA THERAPEUTICS ANNOUNCES UPDATES ON TN-201 GENE THERAPY PROGRAM FOR MYBPC3-ASSOCIATED HCM

* TENAYA THERAPEUTICS INC - INITIAL DATA FROM COHORT 1 TO BE REPORTED IN DECEMBER 2024

* TENAYA THERAPEUTICS : INDEPENDENT DATA SAFETY & MONITORING BOARD ENDORSED DOSE ESCALATION & BROADENING OF ELIGIBILITY CRITERIA; COHORT 2 NOW ENROLLING

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476543791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 04:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476543791","market":"us","top_or_hot":-1,"title":"BRIEF-Tenaya Therapeutics Announces Updates On TN-201 Gene Therapy Program For MYBPC3-Associated HCM","media":"Reuters","content":"<html><body><p>Oct 17 (Reuters) - <a href=\"https://laohu8.com/S/TNYA\">Tenaya Therapeutics Inc</a>   :</p><p>   * TENAYA THERAPEUTICS ANNOUNCES UPDATES ON TN-201 GENE THERAPY PROGRAM FOR MYBPC3-ASSOCIATED HCM</p><p>   * TENAYA THERAPEUTICS INC - INITIAL DATA FROM <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> 1 TO BE REPORTED IN DECEMBER 2024</p><p>   * TENAYA THERAPEUTICS : INDEPENDENT DATA SAFETY &amp; MONITORING BOARD ENDORSED DOSE ESCALATION &amp; BROADENING OF ELIGIBILITY CRITERIA; COHORT 2 NOW ENROLLING</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tenaya Therapeutics Announces Updates On TN-201 Gene Therapy Program For MYBPC3-Associated HCM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tenaya Therapeutics Announces Updates On TN-201 Gene Therapy Program For MYBPC3-Associated HCM\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-18 04:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 17 (Reuters) - Tenaya Therapeutics Inc   :   * TENAYA THERAPEUTICS ANNOUNCES UPDATES ON TN-201 GENE THERAPY PROGRAM FOR MYBPC3-ASSOCIATED HCM   * TENAYA THERAPEUTICS INC - INITIAL DATA FROM COHORT...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2476543791","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476543791","pubTimestamp":1729197466,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 17  - Tenaya Therapeutics Inc   :   * TENAYA THERAPEUTICS ANNOUNCES UPDATES ON TN-201 GENE THERAPY PROGRAM FOR MYBPC3-ASSOCIATED HCM   * TENAYA THERAPEUTICS INC - INITIAL DATA FROM COHORT 1 TO BE REPORTED IN DECEMBER 2024   * TENAYA THERAPEUTICS : INDEPENDENT DATA SAFETY & MONITORING BOARD ENDORSED DOSE ESCALATION & BROADENING OF ELIGIBILITY CRITERIA; COHORT 2 NOW ENROLLINGSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4539":"次新股","BK4007":"制药","TNYA":"Tenaya Therapeutics Inc","LENZ":"Therapeutics","HCM":"和黄医药","BK4531":"中概回港概念"},"translate_title":"简介-Tenaya Therapeutics宣布更新针对MYBPC3相关HCM的TN-201基因治疗计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":0.6,"LENZ":0.6,"TNYA":0.6},"content_text":"Oct 17 (Reuters) - Tenaya Therapeutics Inc   :   * TENAYA THERAPEUTICS ANNOUNCES UPDATES ON TN-201 GENE THERAPY PROGRAM FOR MYBPC3-ASSOCIATED HCM   * TENAYA THERAPEUTICS INC - INITIAL DATA FROM COHORT 1 TO BE REPORTED IN DECEMBER 2024   * TENAYA THERAPEUTICS : INDEPENDENT DATA SAFETY & MONITORING BOARD ENDORSED DOSE ESCALATION & BROADENING OF ELIGIBILITY CRITERIA; COHORT 2 NOW ENROLLINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476543791"}